SynthesisPloS one2024
Respiratory symptoms and pulmonary function in paint industry workers exposed to volatile organic compounds: A systematic review and meta-analysis.
Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Long-term occupational exposure to volatile organic compounds and progressive pulmonary function decline: a 5-year cohort study in the printing industry.Scientific reports · 2026Article
- Association Between Volatile Organic Compound Metabolites in Urine and Adult Lung Function: Evidence From NHANES 2011-2012.The clinical respiratory journal · 2026Article
- Impact of occupational exposure to formaldehyde in Keratin hair treatments on lung function among salon workers: A cross-sectional study.Journal of public health research · 2026Article
- Machine learning prediction of osteoarthritis risk from volatile organic compound exposure using SHAP interpretation in US adults.Scientific reports · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several epidemiological studies have examined the respiratory consequences of occupational exposure to volatile organic compounds (VOCs). However, their effects on paint industry workers in organised and unorganised occupational sectors vary. The present systematic review and meta-analysis aim at evaluating the respiratory symptoms and pulmonary function of paint industry workers from various occupational sectors exposed to VOCs. Relevant MESH terms were used for literature search in MEDLINE, Scopus, Web of Science, and Google Scholar till August 2023. The articles were independently retrieved and qualified by two reviewers and two subject experts arbitrated reviewer differences to establish relevant article inclusion. The systematic review comprised 23 observational studies that assessed respiratory symptom and pulmonary function tests (PFT) among paint industry worker from various occupational sectors. The meta-analysis included 12 studies on respiratory symptoms and 18 on PFT. Pooled meta-analysis was done using random effect model, and the crude odds of respiratory symptoms such as cough (OR: 2.72, 95% confidence interval [CI]: 1.74 to 4.25), dyspnoea (OR: 3.59, 95% CI: 2.13 to 6.05), nasal/throat irritation (OR: 4.5, 95% CI: 1.7 to 12.1), and wheezing (OR: 2.28, 95% CI: 1.37 to 3.82) were significantly higher among paint industry workers exposed to VOC compared to unexposed population. PFT parameters, such as forced expiratory volume in one second (FEV1) (SMD: -0.88, 95% CI: -1.5 to -0.2) and FEV1/forced vital capacity (FEV1/FVC) (SMD: -0.97, 95% CI: -1.6 to -0.32) were found to be significantly reduced among the paint industry workers. The meta-analysis has helped in generating evidence regarding the effect of VOC on respiratory symptoms and pulmonary function and the strength of the association varied with geographical regions, and the type of occupational sectors. Despite the heterogeneity (I2 > 75%) of studies, statistical power of this analysis was significant. Trial registration: PROSPERO registration number: CRD42022311390.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.